PD-1 Inhibitor Improves Outcomes in NHL Subtype PD-1 Inhibitor Improves Outcomes in NHL Subtype
Treatment with the PD-1 inhibitor toripalimab plus radiation therapy improved outcomes in patients with a subtype of non-Hodgkin lymphoma, new data show.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Non-Hodgkin Lymphoma Highlights From SOHO 2023 Non-Hodgkin Lymphoma Highlights From SOHO 2023
Dr Loretta Nastoupil highlights key data in non-Hodgkin lymphoma from SOHO 2023, including safety and efficacy of CAR-T therapies, bispecific antibodies, and mosunetuzumab retreatment.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 27, 2023 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news
McConnell ’ s Bid to Downplay Freezes Undermined by History of Politicians Lying About Their Health
After Senate Minority Leader Mitch McConnell froze during a press conference this month, the Kentucky Republican’s second such episode this summer, his office released a note from the Capitol physician intended to calm those worried about his ability to continue at his job.
Dr. Brian Monahan told McConnell in the letter that there was “no evidence that you have a seizure disorder or that you experienced a stroke, TIA or movement disorder such as Parkinson’s disease.” Monahan suggested the episodes may be related to the Leader’s concussion in March or to dehydration.
[time-brightcove n...
Source: TIME: Health - September 11, 2023 Category: Consumer Health News Authors: Mini Racker Tags: Uncategorized Congress Source Type: news
I was diagnosed with terminal non-Hodgkin's lymphoma cancer aged 20 despite being in peak physical condition - I mistook my symptoms as burnout
Lee Troutman, from Georgia, was diagnosed with late-stage lymphoma last year after suffering from night sweats, fatigue, and liver pain. Before diagnosis, he had worked out 12 hours a day. (Source: the Mail online | Health)
Source: the Mail online | Health - September 6, 2023 Category: Consumer Health News Source Type: news
Response: Alternative approaches for systematic review - Goodman JE, Ticknor RC, Zhou J.
We appreciate the opportunity to respond to the commentaries on our paper, "Systematic Review of Perchloroethylene and Non Hodgkin's Lymphoma." [1] As noted by LaKind et al. [2], there are an overwhelming number of systematic review frameworks, many of whi... (Source: SafetyLit)
Source: SafetyLit - September 1, 2023 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
Student, 22, hit with 'shock' cancer diagnosis shares the first warning sign
The 22-year-old student shared the first symptom of her non-Hodgkin lymphoma struck in her armpit. (Source: Daily Express - Health)
Source: Daily Express - Health - August 28, 2023 Category: Consumer Health News Source Type: news
CAR-T Therapy for NHL Treats Concurrent Rheumatic Disease CAR-T Therapy for NHL Treats Concurrent Rheumatic Disease
CAR –T cell therapy for non-Hodgkin lymphoma appeared as safe and effective in patients with rheumatic autoimmune disease as in those without and also improved control of the underlying autoimmunity.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 24, 2023 Category: Allergy & Immunology Tags: Rheumatology Source Type: news
At age 29 I've survived terminal brain cancer, blood cancer AND a near-fatal car crash
Aria, from Los Angeles, was diagnosed with non-Hodgkins lymphoma, a blood cancer, and underwent 16 brutal surgeries and multiple rounds of chemo, starting her ordeal. (Source: the Mail online | Health)
Source: the Mail online | Health - August 3, 2023 Category: Consumer Health News Source Type: news
At age 28 I've survived terminal brain tumor, blood cancer AND a near-fatal car crash... that's why I call myself the 'CEO of not dying'
Aria, from Los Angeles, was diagnosed with non-Hodgkins lymphoma, a blood cancer, and underwent 16 brutal surgeries and multiple rounds of chemo, starting her ordeal. (Source: the Mail online | Health)
Source: the Mail online | Health - July 27, 2023 Category: Consumer Health News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news
Aurobindo Pharma arm gets USFDA nod for Plerixafor injection
Aurobindo Pharma said Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 25, 2023 Category: Pharmaceuticals Source Type: news
All-Star pitcher Liam Hendriks shares how he closed out cancer at Mayo Clinic in Arizona
Bigger than baseball That's how some describe Liam Hendriks' battle against cancer. At 33 years old, the All-Star Major League Baseball closing pitcher is a fan favorite and famous for throwing fastballs at blazing speeds. But, at only 33 years old, at the end of the 2022 MLB season, Hendriks made the sobering announcement - he had been diagnosed with stage 4 non-Hodgkin's lymphoma. The day after that announcement, Hendriks began cancer treatment at Mayo… (Source: Mayo Clinic Arizona News)
Source: Mayo Clinic Arizona News - July 21, 2023 Category: Hospital Management Source Type: news
Tony Iommi's four-year battle with non-Hodgkin lymphoma - first sign
The legendary rocker has previously said the disease will "probably" come back. (Source: Daily Express - Health)
Source: Daily Express - Health - July 20, 2023 Category: Consumer Health News Source Type: news
European Commission approves Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphomaApproval is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is given for a fixed period of time and made to be readily available, providing patients with a treatment end date and treatment-free periodBasel, 11 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) ha...
Source: Roche Media News - July 11, 2023 Category: Pharmaceuticals Source Type: news
